2022
Anti-SARS-CoV-2 and Autoantibody Profiling of a COVID-19 Patient With Subacute Psychosis Who Remitted After Treatment With Intravenous Immunoglobulin
McAlpine L, Lifland B, Check J, Angarita G, Ngo T, Chen P, Dandekar R, Alvarenga B, Browne W, Pleasure S, Wilson M, Spudich S, Farhadian S, Bartley C. Anti-SARS-CoV-2 and Autoantibody Profiling of a COVID-19 Patient With Subacute Psychosis Who Remitted After Treatment With Intravenous Immunoglobulin. Biological Psychiatry 2022, 93: e25-e29. PMID: 36481066, PMCID: PMC9722219, DOI: 10.1016/j.biopsych.2022.09.007.Peer-Reviewed Original ResearchNervous system consequences of COVID-19
Spudich S, Nath A. Nervous system consequences of COVID-19. Science 2022, 375: 267-269. PMID: 35050660, DOI: 10.1126/science.abm2052.Peer-Reviewed Original Research
2020
Lessons from a neurology consult service for patients with COVID-19
McAlpine LS, Zubair AS, Moeller J, Baehring J, Spudich S. Lessons from a neurology consult service for patients with COVID-19. The Lancet Neurology 2020, 19: 806-807. PMID: 32949536, PMCID: PMC7494315, DOI: 10.1016/s1474-4422(20)30316-1.Peer-Reviewed Case Reports and Technical NotesNeuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019
Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019. JAMA Neurology 2020, 77: 1018-1027. PMID: 32469387, PMCID: PMC7484225, DOI: 10.1001/jamaneurol.2020.2065.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCentral nervous systemCoronavirus disease 2019Nervous systemDisease 2019Respiratory syndromeCOVID-19Severe acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Long-term neurologic sequelaeRespiratory syndrome coronavirus 2Middle East respiratory syndromeSevere acute respiratory syndromeClinical neurological complicationsFurther neuropathological studiesBest treatment algorithmImproved clinical outcomesBlood-brain barrierImpairment of consciousnessSyndrome coronavirus 2Peripheral nervous systemAcute respiratory syndromeHuman coronavirus disease 2019Common neurologic complaintsSARS-CoV-2Neurologic sequelaeStroke Code Presentations, Interventions, and Outcomes Before and During the COVID-19 Pandemic
Jasne AS, Chojecka P, Maran I, Mageid R, Eldokmak M, Zhang Q, Nystrom K, Vlieks K, Askenase M, Petersen N, Falcone GJ, Wira CR, Lleva P, Zeevi N, Narula R, Amin H, Navaratnam D, Loomis C, Hwang DY, Schindler J, Hebert R, Matouk C, Krumholz HM, Spudich S, Sheth KN, Sansing LH, Sharma R. Stroke Code Presentations, Interventions, and Outcomes Before and During the COVID-19 Pandemic. Stroke 2020, 51: 2664-2673. PMID: 32755347, PMCID: PMC7446978, DOI: 10.1161/str.0000000000000347.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBetacoronavirusBrain IschemiaCohort StudiesComorbidityConnecticutCoronary Artery DiseaseCoronavirus InfectionsCOVID-19DyslipidemiasEmergency Medical ServicesEthnicityFemaleHumansHypertensionIncomeInsurance, HealthIntracranial HemorrhagesMaleMedically UninsuredMiddle AgedOutcome and Process Assessment, Health CarePandemicsPneumonia, ViralRetrospective StudiesSARS-CoV-2Severity of Illness IndexStrokeSubstance-Related DisordersTelemedicineThrombectomyThrombolytic TherapyTime-to-TreatmentConceptsComprehensive stroke centerStroke codePatient characteristicsStroke severityStroke code patientsHistory of hypertensionStroke-like symptomsCoronary artery diseaseCoronavirus disease 2019 (COVID-19) pandemicPatient-level dataLower median household incomePublic health initiativesDisease 2019 pandemicCOVID-19 pandemicRace/ethnicityCode patientsHospital presentationPublic health insuranceRankin ScaleStroke centersArtery diseaseReperfusion timeStroke symptomsEarly outcomesConnecticut hospitalsAcute encephalopathy with elevated CSF inflammatory markers as the initial presentation of COVID-19
Farhadian S, Glick LR, Vogels CBF, Thomas J, Chiarella J, Casanovas-Massana A, Zhou J, Odio C, Vijayakumar P, Geng B, Fournier J, Bermejo S, Fauver JR, Alpert T, Wyllie AL, Turcotte C, Steinle M, Paczkowski P, Dela Cruz C, Wilen C, Ko AI, MacKay S, Grubaugh ND, Spudich S, Barakat LA. Acute encephalopathy with elevated CSF inflammatory markers as the initial presentation of COVID-19. BMC Neurology 2020, 20: 248. PMID: 32552792, PMCID: PMC7301053, DOI: 10.1186/s12883-020-01812-2.Peer-Reviewed Original ResearchConceptsInitial presentationCentral nervous system inflammationSARS-CoV-2 infectionCSF inflammatory markersNervous system inflammationCerebrospinal fluid (CSF) cytokinesSeizure-like activityCOVID-19 infectionVirus SARS-CoV-2COVID-19SARS-CoV-2BackgroundCOVID-19Inflammatory markersNeurologic complicationsSystem inflammationImmunocompromised womanNeurologic manifestationsNeurologic symptomsViral neuroinvasionCase presentationWeInfected patientsMental statusRespiratory pathogensConclusionOur findingsInflammation